Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk

The advancement of cancer immunotherapy faces barriers which limit its efficacy. These include weak immunogenicity of the tumor, as well as immunosuppressive mechanisms which prevent effective antitumor immune responses. Recent studies suggest that aberrant expression of cancer testis antigens (CTAs...

Descripción completa

Detalles Bibliográficos
Autores principales: Payne, Kyle K., Toor, Amir A., Wang, Xiang-Yang, Manjili, Masoud H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477552/
https://www.ncbi.nlm.nih.gov/pubmed/23097673
http://dx.doi.org/10.1155/2012/760965

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477552/
https://www.ncbi.nlm.nih.gov/pubmed/23097673
http://dx.doi.org/10.1155/2012/760965

Ejemplares similares